Based on the key indicators related to Monopar Therapeutics' liquidity, profitability, solvency, and operating efficiency, Monopar Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Monopar Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 03/23/2025, Net Invested Capital is likely to grow to about 12.5 M, while Net Tangible Assets are likely to drop slightly above 10.9 M. Key indicators impacting Monopar Therapeutics' financial strength include:
The financial analysis of Monopar Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Monopar Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Monopar Therapeutics competes with Anebulo Pharmaceuticals, Acrivon Therapeutics,, Pmv Pharmaceuticals, Molecular Partners, and Mineralys Therapeutics,. Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Monopar Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Monopar Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Monopar Therapeutics's current stock value. Our valuation model uses many indicators to compare Monopar Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Monopar Therapeutics competition to find correlations between indicators driving Monopar Therapeutics's intrinsic value. More Info.
Monopar Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Monopar Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Monopar Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Monopar Therapeutics Systematic Risk
Monopar Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Monopar Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fifteen with a total number of output elements of fourty-six. The Beta measures systematic risk based on how returns on Monopar Therapeutics correlated with the market. If Beta is less than 0 Monopar Therapeutics generally moves in the opposite direction as compared to the market. If Monopar Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Monopar Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Monopar Therapeutics is generally in the same direction as the market. If Beta > 1 Monopar Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Monopar Therapeutics Thematic Clasifications
Monopar Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Monopar Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Monopar Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Monopar Therapeutics growth as a starting point in their analysis.
Monopar Therapeutics March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Monopar Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Monopar Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Monopar Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Monopar Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Monopar Therapeutics's daily price indicators and compare them against related drivers.
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.